Results 71 to 80 of about 436,093 (357)
Treatment of Relapsed Acute Myeloid Leukemia
Relapse is still a common scenario in acute myeloid leukemia (AML) treatment and occurs in 40–50% of younger and the great majority of elderly patients. The prognosis in relapsed AML patients is generally poor but depends largely on the timing of relapse
F. Thol, A. Ganser
semanticscholar +1 more source
Inhibition of protein SUMOylation has been shown to block tumorigenesis; however, the specific mechanisms by which SUMOylation controls the tumor‐initiating capacities remain elusive. Li et al. describe the role of Etv1 SUMOylation in cancer stem cells using mouse models of mammary gland tumorigenesis.
Veronika Yevdokimova, Yannick D. Benoit
wiley +1 more source
Impact of IDH Mutations on DNA Methylation of Acute Myeloid Leukemia Related Genes: A Review Article
Background: Acute myeloid leukemia is one of the deadliest hematologic malignancies that is marked by genetic alterations, abnormal cellular functions, and proliferation. Mutations in isocitrate dehydrogenase genes, particularly isocitrate dehydrogenase
Duha M. Bayram+2 more
doaj +1 more source
Background Pediatric acute myeloid leukemia is a heterogeneous disease characterized by non-random genetic aberrations related to outcome. The genetic subtype is currently detected by different diagnostic procedures which differ in success rate and/or ...
Brian V. Balgobind+19 more
doaj +1 more source
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.
Acute myeloid leukemia (AML) can develop after an antecedent myeloid malignancy (secondary AML [s-AML]), after leukemogenic therapy (therapy-related AML [t-AML]), or without an identifiable prodrome or known exposure (de novo AML).
R. C. Lindsley+18 more
semanticscholar +1 more source
Immune escape and immunotherapy of acute myeloid leukemia.
In spite of the recent approval of new promising targeted therapies, the clinical outcome of patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for additional and synergistic therapeutic rationales.
L. Vago, I. Gojo
semanticscholar +1 more source
Stemness properties, including quiescence, self‐renewal, and chemoresistance, are closely associated with leukemia relapse. Here, we demonstrate that DNA damage‐inducible transcript 4 (DDIT4) is induced in the hypoxic bone marrow niche and is essential for maintaining the stemness of AML1‐ETO9a leukemia cells.
Yishuang Li+12 more
wiley +1 more source
Background Until recently, few molecular aberrations were recognized in acute lymphoblastic leukemia of T-cell origin; novel lesions have recently been identified and a certain degree of overlap between acute myeloid leukemia and T-cell acute ...
Sabina Chiaretti+14 more
doaj +1 more source
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.
The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in the past few years, driven largely by translational research into its genomic landscape and an improved understanding of mechanisms of resistance to conventional ...
N. Short+6 more
semanticscholar +1 more source
Possible role of human ribonuclease dicer in the regulation of R loops
R loops play an important role in regulating key cellular processes such as replication, transcription, centromere stabilization, or control of telomere length. However, the unscheduled accumulation of R loops can cause many diseases, including cancer, and neurodegenerative or inflammatory disorders. Interestingly, accumulating data indicate a possible
Klaudia Wojcik+2 more
wiley +1 more source